Researchers have developed a new oral formulation of budenoside that has extended release into the colon. In a randomized study of 410 patients with active mild-to-moderate ulcerative colitis, extended-release budenoside (9 mg once daily) was more effective than placebo in inducing combined clinical and endoscopic remission (17.4% versus 4.5%; P = 0.0047) over 8 weeks. The number of adverse events were similar in the two groups.
ORIGINAL RESEARCH PAPER
Travis, S. P. L. et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut doi:10.1136/gutjnl-2012-304258
Rights and permissions
About this article
Cite this article
Extended-release budenoside seems to be safe and effective for ulcerative colitis. Nat Rev Gastroenterol Hepatol 10, 196 (2013). https://doi.org/10.1038/nrgastro.2013.45
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2013.45